Marksans Pharma’s wholly owned subsidiary -- Relonchem in UK has received marketing authorization for its product Exemestane 25mg film-coated tablets from UK Medicines & Healthcare products Regulatory Agency (UK MHRA).
In August 2025, Relonchem had received marketing authorization for Metformin Hydrochloride Relonchem 500 mg, 750 mg and 1000 mg Prolonged Release Tablets.
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
